万维提示：
1、投稿方式：在线投稿。
2、期刊网址：
https://www.karger.com/Journal/Home/224269
3、投稿网址：
https://www.manuscriptmanager.net/OPH?product_id=224269
4、官网邮箱：oph@karger.com（编辑部）
5、官网电话：+41 61 306 1302（编辑部）
6、期刊刊期：双月刊，一年出版6期。
2021年5月31日星期一
投稿须知【官网信息】
Ophthalmologica
Author Guidelines
About the Journal
Aims and Scope
Established since 1899, Ophthalmologica is a frequently cited guide to research in clinical and experimental ophthalmology with a large international circulation and international readership. It contains a selection of patient-oriented contributions covering the etiology of eye diseases, diagnostic techniques, and advances in medical and surgical treatment, with special emphasis on retinal diseases. In addition to original research, the journal regularly features timely reviews to help the readers stay up to date. Ophthalmologica is the official journal of the European Society of Retina Specialists (EURETINA).
Journal Sections
New Technologies in Ophthalmology
EURETINA Lecture
Ophthalmologica Lecture
Mini Reviews: Mini Reviews should contain an easy-to-read literature overview on a specific topic. Papers are either invited or may be submitted for consideration. Only concise articles of no more than 2 printed pages (approx. 6 double-spaced manuscript pages), including an abstract of max. 200 words and references, will be accepted. Please submit your mini review online.
Article Types
Research Article
Research Articles report on primary research. They must describe significant and original observations. Consideration for publication is based on the article’s originality, novelty, and scientific soundness, and the appropriateness of its analysis.
Research Articles are reports of original work. Authors are asked to follow the EQUATOR Network for Research Articles.
Prior approval from an Institutional Review Board (IRB) or an Ethics Review Committee is required for all investigations involving human subjects.
A downloadable template is available below.
Documents
Research Article (DOCX, 28.97 KB)
Review Article
Review Articles are considered reviews of research or summary articles. They are state-of-the-art papers covering a current topic by experts in the field. They should give evidence on and provide answers to a well-defined aspect or question in a particular area. Review Articles must include a critical discussion of the reported data and give a clear conclusion with potential impacts on the standard of care.
A downloadable template is available below.
Documents
Review Article (DOCX, 23.75 KB)
The recommended length is 6 printed pages (approx. 15 double-spaced manuscript pages).
Editorial
Editorials provide a viewpoint on specific articles or on general subjects directly relevant to the journal. Editorials are written by an editor or other member of the journal.
Editorials should not exceed 500 words
A downloadable template is available below.
Documents
Editorial (DOCX, 24.95 KB)
Letter
Letters may explore subjects related to matters discussed in the journal, providing the author’s perspective on a subject. Letters may discuss a recently published article and may lend support or constructively critique the article in line with the author’s experience. The editors reserve the right to share such letters to the authors of the article concerned prior to publication in order to permit response, ideally in the same issue of the journal. Letters should not include original data.
Letters should not exceed 2000 words and have a maximum 15 references & 1 figure/table
A downloadable template is available below.
Documents
Letter (DOCX, 24.24 KB)
Meta-Analysis
Works consisting of studies using a quantitative method of combining the results of independent studies (usually drawn from the published literature) and synthesizing summaries and conclusions which may be used to evaluate therapeutic effectiveness, plan new studies, etc. It is often an overview of clinical trials. We strongly encourage authors to comply with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
A downloadable template is available below.
Documents
Meta-Analysis (DOCX, 26.7 KB)
Contact Information
Should you have any problems with your submission, please contact the editorial office:
Kathrin Gloystein
Editorial Office 'Ophthalmologica'
S. Karger AG
P.O. Box
CH-4009 Basel (Switzerland)
Tel. +41 61 306 1302
Fax +41 61 306 1434
oph@karger.com
Editorial and Journal Policies
General Conditions
Only papers written in English are considered. The articles should be comprehensible to a reader who is fluent in English and should be edited prior to submission to ensure that standard English grammar and usage are observed. Use of a professional language editing service prior to submission can help avoid delays with the review process.
All manuscripts are subject to editorial review.
The presentation of manuscripts should follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals from the International Committee of Medical Journal Editors (ICMJE).
Karger journals aim to adhere to the COPE Code of Conduct and Best Practice Guidelines.
By submitting an article for publication, the authors agree to the transfer of the copyright to the publisher upon acceptance. Accepted papers become the permanent property of the Journal and may not be reproduced by any means, in whole or in part, without the written consent of the publisher.
The Submission Statement with original (hand-written) signatures is to be provided upon submitting the paper. If it is not possible to collect all signatures on a single document, individual copies should be provided for each author.
Karger recommends the use of original images and materials whenever possible. If a submitted manuscript contains third-party copyright material(s), it is the authors’ sole responsibility to obtain permission from the relevant copyright holder for reusing the material(s), including any associated licensing fee. The copyright and usage information needs to be checked carefully to avoid copyright infringement.
Most publishers offer a quick and easy way to clear permissions for their content via the built-in website application RightsLink or via https://www.copyright.com/get-permissions/. Another widely used licensing tool is PLSClear. Please check the publishers’ websites for the available options and user instructions.
Statements
All submitted manuscripts must contain a Statement of Ethics, a Conflict of Interest Statement, an Author Contributions Statement and a Data Availability Statement after the main body of the text, but before the reference list.
Statement of Ethics
Published research must comply with internationally-accepted standards for research practice and reporting. Manuscripts may be rejected if the editors believe that the research has not been carried out within an appropriate ethical framework, and concerns raised after publication may lead to a correction, retraction, or expression of concern in line with COPE guidelines.
Studies involving human subjects (including research on identifiable human material and data) must have been performed with the approval of an appropriate ethics committee and with appropriate participants’ informed consent in compliance with the Helsinki Declaration.
In the manuscript, authors should specify the name of the ethics committee or other relevant authority who approved the study protocol and provide the reference number where appropriate. If ethics approval was not required, or if the study has been granted an exemption from requiring ethics approval, this should also be detailed in the manuscript (including the name of the ethics committee who made that decision).
For all research involving human subjects, written informed consent to participate in the study should be obtained from participants (or their parent/legal guardian where appropriate ) and a statement detailing this should appear in the manuscript. For studies involving vulnerable participants or participants at risk of potential coercion, detailed information regarding the steps taken to ensure informed consent must be provided. If consent was not obtained, please specify why and whether this was approved by the ethics committee.
In line with the ICMJE recommendations on the protection of research participants, authors must avoid providing identifying information unless strictly necessary for the submission and participants’ identifiable attributes must be anonymized in the manuscript and its supplementary files, if any. If identifying information is necessary, authors must confirm that the individual has provided written consent for the use of that information in a publication.
Research involving human embryonic stem cells, embryonic germ cells or induced pluripotent stem cells should comply with the ISSCR 'Guidelines for the Conduct of Human Embryonic Stem Cell Research' or an equivalent set of guidelines or applicable regulations.
Case Reports: Manuscripts reporting a case report must include a statement detailing that written informed consent for publication was obtained and from whom (e.g. “Written informed consent was obtained from the patient for publication of this case report and any accompanying images.”). If the patient has died, consent for publication must be obtained from their next of kin. If the patient described in the case report is a minor or vulnerable, then consent for publication must be obtained from the parent/legal guardian. The completed consent form must be made available to the Editor if requested, and will be treated confidentially.
Clinical Trials: In accordance with the ICMJE recommendations, all clinical trials should be registered in a publicly available registry approved by the WHO or ICMJE (see the list here) and the clinical trial number must be clearly stated in the manuscript. Manuscripts reporting clinical trials must adhere to the relevant reporting guidelines for their study design, such as CONSORT for randomized controlled trials, TREND for non-randomized trials, or other relevant reporting guidelines as detailed on the Equator network website.
Karger follows the WHO definition of clinical trials "A clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes [...] Interventions include but are not restricted to drugs, cells and other biological products, surgical procedures, radiologic procedures, devices, behavioural treatments, process-of-care changes, preventive care, etc. This definition includes Phase I to Phase IV trials.”
Studies involving animals: Experimental research on vertebrates or any regulated invertebrates must have been approved by the authors' Institutional Animal Care and Use Committee (IACUC) or equivalent ethics committee and must follow internationally recognized guidelines such as the ARRIVE guidelines. In the manuscript, authors should specify the name of the ethics committee or other relevant authority who approved the study protocol and provide the reference number where appropriate.
If ethics approval was not required, or if the study has been granted an exemption from requiring ethics approval, this should also be detailed in the manuscript (including the name of the ethics committee who made that decision). Additional information is expected for studies reporting death of a regulated animal as a likely outcome or planned endpoint. Other types of studies including field studies and non-experimental research on animals must comply with local or international guidelines, and where appropriate must have been approved by an appropriate ethics committee.
Conflict of Interest Statement
Karger endorses the ICMJE recommendations on the ‘Disclosure of Financial and Non-Financial Relationships and Activities, and Conflicts of Interest’. Authors are required to disclose any relationship that could reasonably be perceived by a reader as a potential conflict of interest at the time of submission. All forms of support and financial involvement (e.g. employment, consultancies, honoraria, stock ownership and options, expert testimony, grants or patents received or pending, royalties) which took place in the previous three years should be listed, regardless of their potential relevance to the paper. Also the nonfinancial relationships (personal, political, or professional) that may potentially influence the writing of the manuscript should be declared. The role of the funder in study design; collection, analysis, and interpretation of data; writing of the report; any restrictions regarding the submission of the report for publication should be declared. If the funder had no role in any of the above, this should be clearly stated in the manuscript’s funding section.
Author Contributions Statement
In the Author Contributions section, a short statement detailing the contributions of each person named as an author should be included. Contributors to the paper who do not fulfill the ICMJE Criteria for Authorship should be credited in the Acknowledgement section. If an author is removed from or added to the listed authors after submission, an explanation and a signed statement of agreement confirming the requested change are required from all the initially listed authors and from the author to be removed or added.
……
更多详情：
https://www.karger.com/Journal/Guidelines/224269
